Dr Reddy's Laboratories Ltd has launched Supanac (Diclofenac potassium immediate release 50 mg tablets) in India, increasing its offering in the Rs 2700 crore ( $688 million) NSAID market. (Source: IMS ORG June MAT '07).
Supanac is in-licensed from Applied Pharma Research (APR), Switzerland and is used for acute pain management. This patented product has been developed by Dynamic Buffered Technology (DBT) making it a superior formulation of Diclofenac, which reaches peak plasma concentration approximately four times faster than Diclofenac enteric coated preparations thereby ensuring faster pain relief.
No comments:
Post a Comment